March 18, 2023
Pharmabiz
Merck provides update from openlabel arm of phase 2 KeyVibe002 trial of MK7684A, a coformulation of vibostolimab and pembrolizumab, in previously treated patients with metastatic NSCLC
Merck, known as MSD outside of the United States and Canada, provided an update on the open─label arm... See more »
